ArticleInvestigative ophthalmology & visual science2016
Developing an Outcome Measure With High Luminance for Optogenetics Treatment of Severe Retinal Degenerations and for Gene Therapy of Cone Diseases.
Article in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect.Nature medicine · 2019Trial
- How "Micro" Is Microperimetry? Characterizing the Effect of Fundus Tracking on the Psychometric Function.Investigative ophthalmology & visual science · 2026Article
- [Clinical endpoints and translational challenges].Die Ophthalmologie · 2026Review
- Evaluation of Retinal Structure and Visual Function in Blue Cone Monochromacy to Develop Clinical Endpoints for L-opsin Gene Therapy.International journal of molecular sciences · 2024Article
- Blue cone monochromacy and gene therapy.Vision research · 2023Review
- An Engineering Platform for Clinical Application of Optogenetic Therapy in Retinal Degenerative Diseases.IEEE journal of translational engineering in health and medicine · 2023Article
- Article
- High spatial resolution artificial vision inferred from the spiking output of retinal ganglion cells stimulated by optogenetic and electrical means.Frontiers in cellular neuroscience · 2022Article
- The Roles of Optogenetics and Technology in Neurobiology: A Review.Frontiers in aging neuroscience · 2022Review
- Macular Rod Function in Retinitis Pigmentosa Measured With Scotopic Microperimetry.Translational vision science & technology · 2021Article
- Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials.Progress in retinal and eye research · 2021Review
- The functional characteristics of optogenetic gene therapy for vision restoration.Cellular and molecular life sciences : CMLS · 2021Article
- Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium.Translational vision science & technology · 2020Review
- Residual Cone Structure in Patients With X-Linked Cone Opsin Mutations.Investigative ophthalmology & visual science · 2018Article
- Gene-based Therapy in a Mouse Model of Blue Cone Monochromacy.Scientific reports · 2017Article
- Validation and Repeatability of Differential Light Sensitivity Measurements with the Novel MAIA Microperimetry Device.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo present stimuli with varied sizes, colors, and patterns over a large range of luminance.
methodsThe filter bar used in scotopic MP1 was replaced with a custom slide-in tray that introduces light from an external projector driven by an additional computer. MP1 software was modified to provide retinal tracking information to the computer driving the projector. Retinal tracking performance was evaluated by imaging the system input and the output simultaneously with a high-speed video system. Spatial resolution was measured with achromatic and chromatic grating/background combinations over scotopic and photopic ranges.
resultsThe range of retinal illuminance achievable by the modification was up to 6.8 log photopic Trolands (phot-Td); however, in the current work, only a lower range over -4 to +3 log phot-Td was tested in human subjects. Optical magnification was optimized for low-vision testing with gratings from 4.5 to 0.2 cyc/deg. In normal subjects, spatial resolution driven by rods, short wavelength-sensitive (S-) cones, and long/middle wavelength-sensitive (L/M-) cones was obtained by the choice of adapting conditions and wavelengths of grating and background. Data from a patient with blue cone monochromacy was used to confirm mediation.
conclusionsThe modified MP1 can be developed into an outcome measure for treatments in patients with severe retinal degeneration, very low vision, and abnormal eye movements such as those for whom treatment with optogenetics is planned, as well as for patients with cone disorders such as blue cone monochromacy for whom treatment with gene therapy is planned to improve L/M-cone function above a normal complement of rod and S-cone function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.